Provided by Tiger Trade Technology Pte. Ltd.

ResMed

221.10
-1.7300-0.78%
Pre-market: 221.100.00000.00%08:24 EDT
Volume:1.31M
Turnover:290.07M
Market Cap:31.89B
PE:21.20
High:224.04
Open:222.63
Low:220.00
Close:222.83
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:1.36
T/O Rate:0.91%
Dividend:2.40
Dividend Rate:1.09%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:4.84
PE(LYR):21.20

Loading ...

3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build

Simply Wall St.
·
Jul 13

Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34

MT Newswires Live
·
Jul 13

ResMed downgraded to Neutral from Buy at Citi

TIPRANKS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 13

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 11

Resmed is Maintained at Hold by Jefferies

Dow Jones
·
Jul 11

ResMed price target lowered to $225 from $240 at Jefferies

TIPRANKS
·
Jul 10

Jefferies Adjusts Price Target on ResMed to $225 From $240

MT Newswires Live
·
Jul 10

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

TIPRANKS
·
Jul 10

Resmed Inc-statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Jul 10

Statement of Changes in Beneficial Ownership-rmd.n

Reuters
·
Jul 10

ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact

Simply Wall St.
·
Jul 10

Nyxoah: Orin Hirchman-controlled Entities Disclose 14.55% Stake, Crossing 10% Threshold

Reuters
·
Jul 10

Resmed CEO Michael Farrell Sells 4,991 Shares for $1.09 Million

Reuters
·
Jul 09

Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight

MT Newswires Live
·
Jul 09

ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says

MT Newswires Live
·
Jul 09

Resmed Willing to Cut Underperforming Assets

Dow Jones
·
Jul 09

Resmed's $490M Sale Looks Strategically Sound

Dow Jones
·
Jul 09

ResMed: MatrixCare Divestiture Sharpens SaaS Growth Outlook, Supports Attractive Valuation and Reiterated Buy Rating

TIPRANKS
·
Jul 09

ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says

MT Newswires Live
·
Jul 08